Baidu
map

Nat Commun:中科院微生物所高福研究组等揭示MERS-CoV和SARS-CoV刺突蛋白的结构与功能

2017-04-17 佚名 Nature Communicatio

2017年4月10日,国际学术权威刊物自然出版集团旗下子刊《Nature Communications》杂志上在线发表了中国科学院微生物研究所高福、施一研究组和生物物理研究所研究员章新政研究组合作的一篇研究论文,研究解析了近原子分辨率的MERS-CoV和SARS-CoV三聚体刺突蛋白(Spike glycoprotein,S)的电镜结构,与之前发表的其它冠状病毒S蛋白相比,他们发现这两种高致病性病

2017年4月10日,国际学术权威刊物自然出版集团旗下子刊《Nature Communications》杂志上在线发表了中国科学院微生物研究所高福、施一研究组和生物物理研究所研究员章新政研究组合作的一篇研究论文,研究解析了近原子分辨率的MERS-CoV和SARS-CoV三聚体刺突蛋白(Spike glycoprotein,S)的电镜结构,与之前发表的其它冠状病毒S蛋白相比,他们发现这两种高致病性病毒存在自由的受体结合区,更有利于S蛋白和宿主受体的结合,并为后续广谱性抗体和疫苗设计提供了关键的三维结构图谱。中科院微生物所博士生袁园,生物物理所博士曹端方,微生物所博士研究生、天津工业生物技术研究所助理研究员张艳芳,生物物理所博士马军为论文共同第一作者。高福、施一、章新政为论文共同通讯作者。

中东呼吸综合征冠状病毒(MERS-CoV)是重症急性呼吸综合征冠状病毒(SARS-CoV)之后出现的又一个高致病性冠状病毒,已波及全球多个国家和地区,成为威胁世界公共卫生安全的又一严峻挑战。病毒侵入宿主始于病毒表面蛋白与宿主细胞表面特异性受体之间的相互作用。在MERS-CoV、SARS-CoV中,病毒囊膜上的刺突蛋白负责结合受体,决定病毒入侵宿主的能力及组织特异性,是开发预防及治疗冠状病毒引发疾病的药物或疫苗的重要靶向物。

研究人员利用单颗粒冷冻电镜技术解析了近原子分辨率的MERS-CoV和SARS-CoV 三聚体S蛋白的融合前构象结构,分辨率分别为3.7和3.2。这两种高致病性冠状病毒三聚体S蛋白整体结构与已报道的冠状病毒类似,但其受体结合区(RBD)与其他冠状病毒有明显差异。研究者捕获到MERS-CoV和SARS-CoV两种状态的RBD,一种是包埋状(buried)(即为横卧状态,lying state),另一种是暴露状(exposed)(即站立状态,standing state)。已报道的冠状病毒RBD几乎都是包埋状;而MERS-CoV和SARS-CoV均存在暴露状,这种状态的RBD有利于受体的结合,为病毒与细胞表面受体结合机制的阐明提供了理论基础。

另外,研究人员利用X射线晶体学方法首次解析了MERS-NTD和SARS-NTD的结构。S蛋白的N端结构域(N-terminal domain, NTD)在一些冠状病毒中可以结合糖或者受体分子,帮助病毒对宿主细胞的粘附和入侵。但是MERS-NTD和SARS-NTD的结构与功能此前却不清楚。该研究发现这两种病毒NTD独特的糖结合区决定它们不能像有些冠状病毒NTD一样结合糖分子来完成病毒对细胞的粘附作用。此外,S蛋白的NTD和RBD在结构上相邻,因此NTD也有作为中和性抗体作用靶点的潜力。

感染人的六种冠状病毒序列保守性分析发现,融合肽、七肽重复区1(HR1)以及中心螺旋作为相对保守且易于接近的区域,是寻找开发广谱性中和性抗体和抑制剂的理想位点。全长S蛋白三聚体结构的解析对于认知MERS-CoV和SARS-CoV的致病机制具有重要的理论意义,对于靶向病毒侵入过程的特异性药物研发和疫苗设计的实践也至关重要。



图1:MERS-CoV和SARS-CoV S三聚体与受体结合模型图。(a)MERS-CoV S三聚体和受体CD26,(b)SARS-CoV S 三聚体和受体ACE2。



图2:MERS-CoV和SARS-CoV S蛋白的N-连接糖基化分析和针对人冠状病毒可能的抗病毒策略。(a)MERS-CoV S蛋白的N-连接糖基化,(b)SARS-CoV S蛋白的N-连接糖基化,(e-f)人冠状病毒序列保守性分析。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (22)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2086992, encodeId=35a12086992ce, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 22 10:54:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862587, encodeId=d3e1186258e11, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Mon Jan 15 14:54:00 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060456, encodeId=64de2060456ac, content=<a href='/topic/show?id=9c5a3243ef4' target=_blank style='color:#2F92EE;'>#刺突蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32437, encryptionId=9c5a3243ef4, topicName=刺突蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Thu Jul 20 19:54:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805631, encodeId=ec89180563193, content=<a href='/topic/show?id=89e6e8575ae' target=_blank style='color:#2F92EE;'>#结构与功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78575, encryptionId=89e6e8575ae, topicName=结构与功能)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Fri Mar 30 01:54:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824748, encodeId=58261824e4868, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Jul 26 01:54:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937893, encodeId=7d8f193e89389, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jun 23 12:54:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881910, encodeId=04d51881910c1, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 04 21:54:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773409, encodeId=8e7d1e7340931, content=<a href='/topic/show?id=de541156efa' target=_blank style='color:#2F92EE;'>#MERS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11567, encryptionId=de541156efa, topicName=MERS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8b838519264, createdName=meichuangyi, createdTime=Fri Apr 21 06:54:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878204, encodeId=221e18e820419, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Jul 30 12:54:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321128, encodeId=f34b132112844, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Wed Apr 19 12:54:00 CST 2017, time=2017-04-19, status=1, ipAttribution=)]
    2017-09-22 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2086992, encodeId=35a12086992ce, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 22 10:54:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862587, encodeId=d3e1186258e11, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Mon Jan 15 14:54:00 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060456, encodeId=64de2060456ac, content=<a href='/topic/show?id=9c5a3243ef4' target=_blank style='color:#2F92EE;'>#刺突蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32437, encryptionId=9c5a3243ef4, topicName=刺突蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Thu Jul 20 19:54:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805631, encodeId=ec89180563193, content=<a href='/topic/show?id=89e6e8575ae' target=_blank style='color:#2F92EE;'>#结构与功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78575, encryptionId=89e6e8575ae, topicName=结构与功能)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Fri Mar 30 01:54:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824748, encodeId=58261824e4868, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Jul 26 01:54:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937893, encodeId=7d8f193e89389, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jun 23 12:54:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881910, encodeId=04d51881910c1, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 04 21:54:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773409, encodeId=8e7d1e7340931, content=<a href='/topic/show?id=de541156efa' target=_blank style='color:#2F92EE;'>#MERS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11567, encryptionId=de541156efa, topicName=MERS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8b838519264, createdName=meichuangyi, createdTime=Fri Apr 21 06:54:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878204, encodeId=221e18e820419, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Jul 30 12:54:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321128, encodeId=f34b132112844, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Wed Apr 19 12:54:00 CST 2017, time=2017-04-19, status=1, ipAttribution=)]
    2018-01-15 gous
  3. [GetPortalCommentsPageByObjectIdResponse(id=2086992, encodeId=35a12086992ce, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 22 10:54:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862587, encodeId=d3e1186258e11, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Mon Jan 15 14:54:00 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060456, encodeId=64de2060456ac, content=<a href='/topic/show?id=9c5a3243ef4' target=_blank style='color:#2F92EE;'>#刺突蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32437, encryptionId=9c5a3243ef4, topicName=刺突蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Thu Jul 20 19:54:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805631, encodeId=ec89180563193, content=<a href='/topic/show?id=89e6e8575ae' target=_blank style='color:#2F92EE;'>#结构与功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78575, encryptionId=89e6e8575ae, topicName=结构与功能)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Fri Mar 30 01:54:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824748, encodeId=58261824e4868, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Jul 26 01:54:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937893, encodeId=7d8f193e89389, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jun 23 12:54:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881910, encodeId=04d51881910c1, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 04 21:54:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773409, encodeId=8e7d1e7340931, content=<a href='/topic/show?id=de541156efa' target=_blank style='color:#2F92EE;'>#MERS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11567, encryptionId=de541156efa, topicName=MERS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8b838519264, createdName=meichuangyi, createdTime=Fri Apr 21 06:54:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878204, encodeId=221e18e820419, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Jul 30 12:54:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321128, encodeId=f34b132112844, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Wed Apr 19 12:54:00 CST 2017, time=2017-04-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2086992, encodeId=35a12086992ce, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 22 10:54:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862587, encodeId=d3e1186258e11, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Mon Jan 15 14:54:00 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060456, encodeId=64de2060456ac, content=<a href='/topic/show?id=9c5a3243ef4' target=_blank style='color:#2F92EE;'>#刺突蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32437, encryptionId=9c5a3243ef4, topicName=刺突蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Thu Jul 20 19:54:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805631, encodeId=ec89180563193, content=<a href='/topic/show?id=89e6e8575ae' target=_blank style='color:#2F92EE;'>#结构与功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78575, encryptionId=89e6e8575ae, topicName=结构与功能)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Fri Mar 30 01:54:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824748, encodeId=58261824e4868, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Jul 26 01:54:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937893, encodeId=7d8f193e89389, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jun 23 12:54:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881910, encodeId=04d51881910c1, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 04 21:54:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773409, encodeId=8e7d1e7340931, content=<a href='/topic/show?id=de541156efa' target=_blank style='color:#2F92EE;'>#MERS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11567, encryptionId=de541156efa, topicName=MERS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8b838519264, createdName=meichuangyi, createdTime=Fri Apr 21 06:54:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878204, encodeId=221e18e820419, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Jul 30 12:54:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321128, encodeId=f34b132112844, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Wed Apr 19 12:54:00 CST 2017, time=2017-04-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2086992, encodeId=35a12086992ce, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 22 10:54:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862587, encodeId=d3e1186258e11, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Mon Jan 15 14:54:00 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060456, encodeId=64de2060456ac, content=<a href='/topic/show?id=9c5a3243ef4' target=_blank style='color:#2F92EE;'>#刺突蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32437, encryptionId=9c5a3243ef4, topicName=刺突蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Thu Jul 20 19:54:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805631, encodeId=ec89180563193, content=<a href='/topic/show?id=89e6e8575ae' target=_blank style='color:#2F92EE;'>#结构与功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78575, encryptionId=89e6e8575ae, topicName=结构与功能)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Fri Mar 30 01:54:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824748, encodeId=58261824e4868, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Jul 26 01:54:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937893, encodeId=7d8f193e89389, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jun 23 12:54:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881910, encodeId=04d51881910c1, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 04 21:54:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773409, encodeId=8e7d1e7340931, content=<a href='/topic/show?id=de541156efa' target=_blank style='color:#2F92EE;'>#MERS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11567, encryptionId=de541156efa, topicName=MERS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8b838519264, createdName=meichuangyi, createdTime=Fri Apr 21 06:54:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878204, encodeId=221e18e820419, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Jul 30 12:54:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321128, encodeId=f34b132112844, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Wed Apr 19 12:54:00 CST 2017, time=2017-04-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2086992, encodeId=35a12086992ce, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 22 10:54:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862587, encodeId=d3e1186258e11, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Mon Jan 15 14:54:00 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060456, encodeId=64de2060456ac, content=<a href='/topic/show?id=9c5a3243ef4' target=_blank style='color:#2F92EE;'>#刺突蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32437, encryptionId=9c5a3243ef4, topicName=刺突蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Thu Jul 20 19:54:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805631, encodeId=ec89180563193, content=<a href='/topic/show?id=89e6e8575ae' target=_blank style='color:#2F92EE;'>#结构与功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78575, encryptionId=89e6e8575ae, topicName=结构与功能)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Fri Mar 30 01:54:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824748, encodeId=58261824e4868, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Jul 26 01:54:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937893, encodeId=7d8f193e89389, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jun 23 12:54:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881910, encodeId=04d51881910c1, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 04 21:54:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773409, encodeId=8e7d1e7340931, content=<a href='/topic/show?id=de541156efa' target=_blank style='color:#2F92EE;'>#MERS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11567, encryptionId=de541156efa, topicName=MERS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8b838519264, createdName=meichuangyi, createdTime=Fri Apr 21 06:54:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878204, encodeId=221e18e820419, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Jul 30 12:54:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321128, encodeId=f34b132112844, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Wed Apr 19 12:54:00 CST 2017, time=2017-04-19, status=1, ipAttribution=)]
    2017-06-23 hukaixun
  7. [GetPortalCommentsPageByObjectIdResponse(id=2086992, encodeId=35a12086992ce, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 22 10:54:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862587, encodeId=d3e1186258e11, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Mon Jan 15 14:54:00 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060456, encodeId=64de2060456ac, content=<a href='/topic/show?id=9c5a3243ef4' target=_blank style='color:#2F92EE;'>#刺突蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32437, encryptionId=9c5a3243ef4, topicName=刺突蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Thu Jul 20 19:54:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805631, encodeId=ec89180563193, content=<a href='/topic/show?id=89e6e8575ae' target=_blank style='color:#2F92EE;'>#结构与功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78575, encryptionId=89e6e8575ae, topicName=结构与功能)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Fri Mar 30 01:54:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824748, encodeId=58261824e4868, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Jul 26 01:54:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937893, encodeId=7d8f193e89389, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jun 23 12:54:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881910, encodeId=04d51881910c1, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 04 21:54:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773409, encodeId=8e7d1e7340931, content=<a href='/topic/show?id=de541156efa' target=_blank style='color:#2F92EE;'>#MERS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11567, encryptionId=de541156efa, topicName=MERS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8b838519264, createdName=meichuangyi, createdTime=Fri Apr 21 06:54:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878204, encodeId=221e18e820419, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Jul 30 12:54:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321128, encodeId=f34b132112844, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Wed Apr 19 12:54:00 CST 2017, time=2017-04-19, status=1, ipAttribution=)]
    2017-10-04 liye789132251
  8. [GetPortalCommentsPageByObjectIdResponse(id=2086992, encodeId=35a12086992ce, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 22 10:54:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862587, encodeId=d3e1186258e11, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Mon Jan 15 14:54:00 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060456, encodeId=64de2060456ac, content=<a href='/topic/show?id=9c5a3243ef4' target=_blank style='color:#2F92EE;'>#刺突蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32437, encryptionId=9c5a3243ef4, topicName=刺突蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Thu Jul 20 19:54:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805631, encodeId=ec89180563193, content=<a href='/topic/show?id=89e6e8575ae' target=_blank style='color:#2F92EE;'>#结构与功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78575, encryptionId=89e6e8575ae, topicName=结构与功能)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Fri Mar 30 01:54:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824748, encodeId=58261824e4868, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Jul 26 01:54:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937893, encodeId=7d8f193e89389, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jun 23 12:54:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881910, encodeId=04d51881910c1, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 04 21:54:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773409, encodeId=8e7d1e7340931, content=<a href='/topic/show?id=de541156efa' target=_blank style='color:#2F92EE;'>#MERS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11567, encryptionId=de541156efa, topicName=MERS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8b838519264, createdName=meichuangyi, createdTime=Fri Apr 21 06:54:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878204, encodeId=221e18e820419, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Jul 30 12:54:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321128, encodeId=f34b132112844, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Wed Apr 19 12:54:00 CST 2017, time=2017-04-19, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2086992, encodeId=35a12086992ce, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 22 10:54:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862587, encodeId=d3e1186258e11, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Mon Jan 15 14:54:00 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060456, encodeId=64de2060456ac, content=<a href='/topic/show?id=9c5a3243ef4' target=_blank style='color:#2F92EE;'>#刺突蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32437, encryptionId=9c5a3243ef4, topicName=刺突蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Thu Jul 20 19:54:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805631, encodeId=ec89180563193, content=<a href='/topic/show?id=89e6e8575ae' target=_blank style='color:#2F92EE;'>#结构与功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78575, encryptionId=89e6e8575ae, topicName=结构与功能)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Fri Mar 30 01:54:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824748, encodeId=58261824e4868, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Jul 26 01:54:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937893, encodeId=7d8f193e89389, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jun 23 12:54:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881910, encodeId=04d51881910c1, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 04 21:54:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773409, encodeId=8e7d1e7340931, content=<a href='/topic/show?id=de541156efa' target=_blank style='color:#2F92EE;'>#MERS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11567, encryptionId=de541156efa, topicName=MERS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8b838519264, createdName=meichuangyi, createdTime=Fri Apr 21 06:54:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878204, encodeId=221e18e820419, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Jul 30 12:54:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321128, encodeId=f34b132112844, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Wed Apr 19 12:54:00 CST 2017, time=2017-04-19, status=1, ipAttribution=)]
    2017-07-30 anminleiryan
  10. [GetPortalCommentsPageByObjectIdResponse(id=2086992, encodeId=35a12086992ce, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Sep 22 10:54:00 CST 2017, time=2017-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862587, encodeId=d3e1186258e11, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Mon Jan 15 14:54:00 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060456, encodeId=64de2060456ac, content=<a href='/topic/show?id=9c5a3243ef4' target=_blank style='color:#2F92EE;'>#刺突蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32437, encryptionId=9c5a3243ef4, topicName=刺突蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Thu Jul 20 19:54:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805631, encodeId=ec89180563193, content=<a href='/topic/show?id=89e6e8575ae' target=_blank style='color:#2F92EE;'>#结构与功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78575, encryptionId=89e6e8575ae, topicName=结构与功能)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Fri Mar 30 01:54:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824748, encodeId=58261824e4868, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Wed Jul 26 01:54:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937893, encodeId=7d8f193e89389, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Jun 23 12:54:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881910, encodeId=04d51881910c1, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 04 21:54:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773409, encodeId=8e7d1e7340931, content=<a href='/topic/show?id=de541156efa' target=_blank style='color:#2F92EE;'>#MERS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11567, encryptionId=de541156efa, topicName=MERS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8b838519264, createdName=meichuangyi, createdTime=Fri Apr 21 06:54:00 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878204, encodeId=221e18e820419, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Jul 30 12:54:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321128, encodeId=f34b132112844, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Wed Apr 19 12:54:00 CST 2017, time=2017-04-19, status=1, ipAttribution=)]
    2017-04-19 小刀医生

相关资讯

STM:新型冠状病毒中和抗体初研成功能

    中美两个独立的研究团队28日报告说,他们发现了多株可以抑制新型冠状病毒(中东呼吸系统综合征冠状病毒)感染的中和抗体。 这是国际上首次报告发现抗新型冠状病毒的中和抗体。中和抗体是免疫细胞分泌的一类蛋白,能在某些病毒侵入细胞之前与该病毒结合,阻止其黏附、感染细胞,相当于把病毒“中和”掉。 清华大学张林琦教授和王新泉教授带领的团

MERS病例飙升敲响警钟

由于担心MERS传染,利雅得球场工作人员戴口罩进行工作 图片来源:FAYEZ NURELDINE 科学家正努力弄清中东呼吸系统综合征(MERS)冠状病毒感染人数急剧增加的原因。仅在4月,沙特阿拉伯和阿拉伯联合酋长国已经报告超过200个新病例。美国疾病控制和预防中心也于5月2日通报说,该国确诊境内首位感染MERS病毒的患者,并称不排除因患者此前接触他人而造成更大范围传播

Nature:科学家发现中和冠状病毒的新线索

图片来源:medicalxpress.com 2003年发生的SARS(严重急性呼吸器官综合征)引发了至少775人死亡,2012年MERS(中东呼吸综合征)又开始在人群中肆虐,其病死率为36%,这些疾病均是由冠状病毒而引发的,该病毒可以发生快速进化,从而从动物群体中传染至人类机体。 近日刊登于国际杂志Nature上的一项研究论文中,来自斯克利普斯研究所、达特茅斯医学院及美国国立卫生研究院等

WHO :骆驼体内发现中东新型冠状病毒

       骆驼体内发现了中东呼吸系统综合征冠状病毒。 图片来源:Wikimedia 越来越多的迹象表明,骆驼可能与去年在中东地区传播的一种新的致命病毒有关。世界卫生组织(WHO)近日宣布在卡塔尔的一群骆驼中发现了中东呼吸系统综合征(MERS)冠状病毒,这些病毒与最近的两例人感染病有关。 “这是谜题最关键的一块。”美国明尼苏达大学传染病研究和政策中心

PNAS:发现对抗MERS冠状病毒的抗体

一个国际研究小组发现了一种MERS中和抗体,该发现可能会对MERS病毒感染者的治疗有帮助。他们的文章发表在《美国国家科学院学报》上,该研究小组描述了他们进行的研究结果以及为什么他们认为他们所发现的可能会对这种致命的疾病能够预防和治疗。 中东呼吸系统综合症冠状病毒(MERS-CoV)是一种疾病,它会导致严重的呼吸道疾病感染并且死亡率很高。它被认为中东地区的人类从骆驼(骆驼的病毒来自蝙蝠)身上

我国科学家发现冠状病毒编码校正分子机制

中科院上海生科院生化细胞所国家蛋白质科学中心·上海(筹)特聘研究员兼清华大学教授饶子和与该中心研究员张荣光领导团队,在新发MERS/SARS冠状病毒研究中取得重要进展,首次揭示了nsp14-nsp10复合体的结构基础,阐明了冠状病毒编码校正的分子机制,相关研究成果已在线发表于美国《国家科学院院刊》。 冠状病毒是目前基因组最大的一种RNA病毒,能够感染人类,引起多种急性和慢性疾病,其中最引人

Baidu
map
Baidu
map
Baidu
map